Semaglutide 20 mg

This 20 mg vial of Semaglutide is supplied as a higher-content format for extended-duration research applications. Semaglutide is a synthetic 31-residue acylated GLP-1 analog engineered for high-affinity binding to the glucagon-like peptide-1 (GLP-1) receptor and for extended plasma residency through reversible albumin binding. It is supplied as an investigational laboratory peptide for use in GLP-1 receptor signaling research and incretin-pathway research models.

Semaglutide differs from native human GLP-1 by three key structural modifications: substitution of alanine at position 8 with α-aminoisobutyric acid (Aib) for resistance to dipeptidyl peptidase-4 cleavage, attachment of a C18 fatty diacid via a γGlu-2xOEG spacer to a lysine residue, and a Lys→Arg substitution at position 34. These modifications, characterized in detail in the original discovery paper, give semaglutide its hallmark albumin-binding profile and extended laboratory pharmacokinetics (Lau et al., 2015, Journal of Medicinal Chemistry).

In laboratory research studies, semaglutide is used as a reference GLP-1 receptor agonist for investigating cyclic AMP signaling, β-arrestin recruitment, receptor trafficking, and biased agonism. It is also widely studied in cellular research models of pancreatic islet biology, hepatic energy-metabolism research, central-nervous-system GLP-1 receptor distribution mapping, and structure–activity research comparing semaglutide with native GLP-1, liraglutide, and dual-incretin analogs such as tirzepatide.

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.

Glucagon-like peptide-1 (GLP-1) is an incretin peptide produced by intestinal L-cells that engages the GLP-1 receptor, a class B G-protein-coupled receptor expressed across pancreatic islets, the central nervous system, the cardiovascular system, and several peripheral tissues. Native GLP-1 has an extremely short plasma half-life because it is rapidly cleaved by dipeptidyl peptidase-4 (DPP-4), which historically limited its usefulness as a laboratory research compound. Structural engineering of acylated GLP-1 analogs was therefore a major area of incretin-pathway research.

Semaglutide emerged from a discovery program that systematically optimized acylation chemistry and sequence modifications to balance DPP-4 resistance, albumin affinity, and GLP-1 receptor agonism. Its three engineered modifications, Aib8, the C18 fatty diacid side chain with γGlu-2xOEG linker, and the Arg34 substitution, collectively give the molecule its extended plasma residency in laboratory species and its high-affinity binding at the GLP-1 receptor.

This structural profile has made semaglutide a widely used reference compound in GLP-1 receptor signaling research, including studies of cyclic AMP accumulation, β-arrestin recruitment, receptor internalization kinetics, and biased agonism. Research models also investigate semaglutide in the context of pancreatic beta-cell research, hepatic energy-metabolism research, central GLP-1 receptor mapping, and comparative pharmacology against native GLP-1 and dual-incretin analogs.

1. GLP-1 Receptor Engagement

Semaglutide binds the GLP-1 receptor, a class B G-protein-coupled receptor, with high affinity. Research models indicate that this interaction stabilizes an active receptor conformation that engages Gαs and modulates intracellular cyclic AMP, the canonical second messenger downstream of the GLP-1 receptor in pancreatic beta-cell research and other tissues expressing the receptor.

2. Cyclic AMP Signaling and Downstream Kinases

Upon receptor activation, semaglutide modulates adenylyl cyclase and downstream protein kinase A signaling, as well as EPAC-mediated pathways. These cascades are widely studied in incretin-pathway research as regulators of gene expression in pancreatic islet research models, including transcription of genes involved in glucose-signalling and beta-cell research markers.

3. Biased Agonism and Receptor Trafficking

Laboratory research studies have characterized semaglutide's signaling profile at the GLP-1 receptor with respect to cyclic AMP versus β-arrestin recruitment. Comparative research with native GLP-1, liraglutide, and dual-incretin analogs investigates how biased agonism and receptor internalization kinetics relate to extended receptor residency in cellular research models.

4. Albumin Binding and Extended Plasma Residency

The C18 fatty diacid side chain, attached through a γGlu-2xOEG spacer to Lys26, enables reversible binding to serum albumin. This structural feature is investigated in pharmacokinetics research as the basis for semaglutide's extended plasma half-life in laboratory species, supporting its use as a long-acting reference compound in GLP-1 receptor signaling research.

Research Applications

Conclusion

Semaglutide is a structurally optimized acylated GLP-1 receptor agonist that has become one of the most widely used reference compounds in GLP-1 receptor signaling research. Its combination of DPP-4 resistance, albumin-mediated pharmacokinetic extension, and high-affinity GLP-1 receptor binding makes it a valuable investigational laboratory peptide for laboratory research studies in incretin-pathway research and metabolic-pathway research models.

Research Use Disclaimer

This product is intended for research and laboratory use only. It is designed exclusively for in vitro research purposes. All information provided is for educational and research reference only. This product is not intended for human or animal use. It is not a drug, food, or cosmetic and must not be marketed, labeled, or used as such. Use and handling are restricted to trained and qualified professionals.